Conference Coverage

Anti-TNF agents may slow erosive hand osteoarthritis

Publish date: June 9, 2016

 

AT THE EULAR 2016 CONGRESS

References

Pfizer and UCB supported the investigator-initiated studies and provided the study drugs. Dr. Kloppenburg has received lecturing, consultancy, and investigator fees or grants from AbbVie, APPROACH, GlaxoSmithKline, Levicept, Pfizer, Servier, and UCB, all paid to her institution. All other authors declared no conflicts of interests.

rhnews@frontlinemedcom.com

Pages

Recommended Reading

Persistent knee pain predicts structural osteoarthritis early
MDedge Rheumatology
Sustained-release steroid provides prolonged OA pain relief
MDedge Rheumatology
Osteoarthritis hip pain follows four distinct paths
MDedge Rheumatology
Blood biomarker panel studies aim to predict knee osteoarthritis, progression
MDedge Rheumatology
Physical therapy underused for knee osteoarthritis
MDedge Rheumatology
Guideline change advocated on using acetaminophen for OA
MDedge Rheumatology
Allogeneic cell therapy fares well in phase III osteoarthritis trial
MDedge Rheumatology
Opioid-based therapies reduce TKA needs for OA patients, but not costs
MDedge Rheumatology
Adolescent knee pain ‘not benign,’ linked to later OA
MDedge Rheumatology
Phone coaching adds limited benefits in knee osteoarthritis
MDedge Rheumatology